PeptideStack
5.2kquestions
20kanswers
220users

Why do two lots from the same vendor differ by nine per cent on content?

Asked 3 Jan 2025Modified 16 months agoViewed 9.2k times
12

I have both a purity figure and a content figure, which is why the discrepancy is visible.

An unexpected observation, and I would like a differential rather than reassurance.

The conditions were within what I understood to be the acceptable range, which is why I am asking.

What is the differential here, and which test discriminates between the options?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

476 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

454 questions
shareeditfollowflag
TW
askedtare_weight60k1483 Jan 2025
7Same question came up on a different supplier and the answer was entirely about the method. – tess_amankwah 9 months ago
add a comment

5 Answers

Accepted answer first, then by votes
59

Accepted answer

Nine per cent between two lots of the same product is a process-control statement: on a 10 mg label that is 0.9 mg of difference, which is more than three times the couple of per cent an assay against a good reference standard contributes. So it is a real difference between the lots rather than a disagreement between two measurements — which is the first thing to establish, and it is established by arithmetic rather than by argument. Then the candidate causes, in descending order of likelihood. Residual water: net peptide content excludes it, and a cake that was dried differently reads differently on the same peptide. Counter-ion: acetate and trifluoroacetate have different masses and different stoichiometries, and neither is peptide. Fill variation at the vialling step. And only after those three, an actual difference in the synthesis. Which means the diagnostic request is not "why is lot B low" but a Karl Fischer water figure and a counter-ion figure for both lots. Nine per cent is comfortably within what water plus counter-ion can account for on their own. A supplier who cannot produce those two numbers per lot is telling you what their process control is, whatever the certificate says.

Concretely, thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

Mass shifts and what they usually mean

Δ mass (Da)Most likely causeDistinguishing feature
+1Deamidation (Asn or Gln)New peak, slightly earlier retention
−17Loss of ammoniaOften with deamidation
−18Dehydration / succinimidepH-dependent, reversible
+16Oxidation (Met, Trp)Earlier retention, light-related
−128Missing Gln or LysDeletion sequence from synthesis
0Isomer: racemisation or scramblingSame mass, shifted retention

The relevant detail is that the statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
TM
answered · acceptedtobias_maartens171k35814 Feb 2025
This should be linked from the help pages. – j_wierzbicki 2 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
24

Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

Put another way, if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
AB
answeredassay_blank45k382 Feb 2025
7Two of us submitted the same lot to different laboratories and got results a tenth apart. – k_szabo 4 months ago
8Adding for future readers: the certificate should carry the lot number, not just a batch code. – tobias_maartens 6 months ago
add a comment
16

Specifically, two vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
SD
answeredsiobhan_deasy9.5k1522 Jan 2025
5The impurity table is the part I now read first, and this explains why. – RP_C18 2 months ago
add a comment
13

Most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

edited 25 Jan 2025 by anouk_desmet — updated for the 2026 guidance change

shareimprove this answerflag
AD
answeredanouk_desmet16k3811 Jan 2025
10

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

edited 8 Apr 2025 by fibre_or_fragment — reworded for clarity after a comment

shareimprove this answerflag
FF
answeredfibre_or_fragment13k3830 Mar 2025
The system-suitability data is the part that tells you whether to believe the rest. – w_okoye 17 hours ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.